NovaBiotics Ltd

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in

NovaBiotics Ltd. is making plans to progress its oral treatment for cystic fibrosis exacerbations into Phase III by early next year, after reporting positive Phase IIb results. The company is hopeful

The table records clinical developments using data from Informa Pharma Intelligence’s Biomedtracker. It lists drugs for which an important event was recorded between Dec. 23 and Dec. 29, 2016, divided

Shares in companies engaged in antibiotic development basked in the reflected glow of Merck & Co's just announced $9.5bn takeout deal for Cubist Pharmaceuticals (scripintelligence.com, 9 December 2014